The phase 2b trial of Zimura (avacincaptad pegol) – a complement C5 inhibitor – reduced the rate of geographic atrophy (GA) in people with dry AMD compared to a control group. GA is the ...
News Medical on MSN7d
USC researchers receive $6 million to advance dry AMD treatmentThe California Institute for Regenerative Medicine (CIRM), the state's stem cell agency, has awarded a two-year, $6 million ...
Dry AMD is one of the two forms of the ocular disease that ranks as the leading cause of blindness in adults over age 65, driven by the slow loss of photoreceptor cells over time. Dry AMD begins ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback